{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-086140","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.915551+00:00","generated_at":"2026-06-17T08:19:38.149924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SeaStar Medical reports 2022 net loss of $23.0M; cash only $47K","bullets":["Net loss $23.0M ($2.80/share) vs $4.6M ($0.63/share) in 2021; G&A expenses rose to $6.6M from $1.7M.","Cash at Dec 31, 2022 was $47,000, down from $510,000; company raised $3.3M in March 2023 convertible debt.","SCD device for adult AKI: NEUTRALIZE-AKI trial to enroll up to 200 patients; expects FDA PMA filing in Q3 2024.","Pediatric AKI HDE application under FDA review; license/distribution agreement with Nuwellis for top 50 U.S. hospitals.","R&D expenses flat at $2.8M; other expense surged to $11.4M from $0.2M, driven by $10.2M loss on forward option."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-086140","json":"https://secwatch.observer/filing/0001193125-23-086140.json","markdown":"https://secwatch.observer/filing/0001193125-23-086140.md","text":"https://secwatch.observer/filing/0001193125-23-086140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000119312523086140/0001193125-23-086140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000119312523086140/d492852d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:19:38.149924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fab14c00b2d1625ce4b1f2fbd46755748818006","claim":"SeaStar Medical Holding Corp reported the year ended December 31, 2022 results: net income $23.0 million, or $2.80 per share, EPS $2.80 per share.","evidence_excerpt":"SeaStar Medical Reports 2022 Financial Results and Provides a Business Update DENVER (March 30, 2023) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831868/000119312523086140/0001193125-23-086140-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$23.0 million, or $2.80 per share"},{"label":"EPS","value":"$2.80 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}